By Dr. Chris Saunter, Originally published in Drug Target Review, April 2026 In the wake of recent government policy aimed […]
Why lower organisms matter for neurodegeneration drug discovery Read Post »
Artificial intelligence and machine learning are rapidly reshaping how pharmaceutical companies discover and prioritise new compounds [1]. From virtual screening
VivoScan™: Abundant Whole-Organism Data for AI-driven Drug Discovery Pipelines Read Post »
Between exponential investment into AI technologies, changing global superpowers, and strategic shifts within the field, the current moment could mark a paradigm shift in drug development. Coming off the heels of a
Let the Worm Wiggle into the Pipeline: The Case for C. elegans in Modern Drug Discovery Read Post »
BioAscent Discovery Ltd. is a leading provider of integrated drug discovery services, including compound management, chemistry, DMPK, biophysics and more. Magnitude Biosciences
C. elegans: a Game Changer for Scalable Gut-Brain Axis Research
Tackling the Translational Gap with Whole-Organism HTS Read Post »
Accelerate smarter drug discovery with VivoScan™: a breakthrough high-throughput screening platform from Magnitude Biosciences. Using live C. elegans as a
VivoScan™ Data Insight Pack Read Post »
WormGazer™ Video: Reproductive Toxicity of Etoxazole in C. elegans
WormGazer™ Video: Reproductive Toxicity of Etoxazole in C. elegans Read Post »
WormGazer™ in Action: C. elegans Mobility Decline
WormGazer™ Video: C. elegans Mobility Decline Read Post »
Magnitude Biosciences, a specialist contract research organisation (CRO) in County Durham offering in vivo discovery of treatments for age-related conditions
C. elegans: a Game Changer for Scalable Gut-Brain Axis Research
C. elegans: a Game Changer for Scalable Gut-Brain Axis Research Read Post »
